Clinical trialObservationalRecruiting
Role of Exosomes in Pancreatic Cancer Progression
- Outcome
- Ongoing
- Phase
- Observational
- Status
- Recruiting
- Study type
- Observational
- Start
- 22 May 2022
- Expected end
- 30 April 2027
- Enrollment
- 60 participants
- Sites
- 1
- Primary outcomes
- Characterise the extracellular vesicle/exosome content of patients with pancreatic carcinoma.
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 15 January 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The present pilot study is set up with the objective of identifying circulating markers in the biological fluids (blood and urine) of subjects with pancreatic carcinoma and their association with disease stage, to evaluate their potential use as predictive and diagnostic markers for this tumor of difficult early diagnosis and often inauspicious prognosis.
Detailed description public domain (ClinicalTrials.gov)
The study is cross-sectional, single-center, spontaneous, in human tissues. It is a pilot study to gather evidence on the content of extracellular vesicles/exosomes in patients with pancreatic cancer. The study will be performed on tumor tissue, blood and urine samples. Tissue will be obtained by needle biopsy (fine needle biopsy - FNB) during echoendoscopic examination. The study aims to characterize the content of extracellular vesicles/exosomes in the biological fluids of subjects with pancreatic cancer with the goal of identifying new markers for this disease. To this end, the following will be carried out: * an ex vivo and in vitro characterization study of the secretion of these extracellular vesicles/exosomes with analysis of their contents in terms of proteins and nucleic acids; * a study of the mechanisms of epithelial-mesenchymal transition (EMT), invasion and aggressiveness to highlight a possible association between the secretion of these vesicles and the oncological stage of pancreatic carcinoma;
Primary outcome public domain (ClinicalTrials.gov)
Characterise the extracellular vesicle/exosome content of patients with pancreatic carcinoma.. The study aims to characterize the extracellular vesicles/exosomes content in the biological fluids of subjects suffering from pancreatic carcinoma with the aim of identifying new markers for this disease. To this end, the following will be carried out: * a study of ex vivo and in vitro characterisation of the secretion of these extracellular vesicles/exosomes with analysis of their content in terms of proteins and nucleic acids; * a study of mesenchymal epithelium transition (EMT), invasion and aggression mechanisms to highlight a possible association between secretion of these vesicles and the oncological stage of pancreatic carcinoma; Time frame: At baseline, visit V1..
Eligibility public domain (ClinicalTrials.gov)
Inclusion criteria: * People with pancreatic cancer * 18 years old * Obtaining informed consent. Exclusion criteria: * Patients who do not need or cannot perform endoscopy with biopsy sampling; * patients with a previous or active neoplastic pathology, different from pancreatic neoplasia.
Enrollment public domain (ClinicalTrials.gov)
Enrollment: 60 participants (estimated).